Imagine a world where the involuntary repetition of thoughts and actions, coupled with crippling anxiety, is a daily reality. This isn't a dystopian novel; it's the life of approximately 2% of the global population suffering from Obsessive-compulsive disorder (OCD). A condition that doesn't discriminate by age, it often casts its victims into a vortex of isolation as they're ensnared by their own obsessions, sidelining relationships, work, and even simple joys.

Traditional treatments? Cognitive-behavioral therapy (CBT) and antidepressants. But here's the rub: they're slow to show results, and for a staggering 30-40% of patients, they might as well be sugar pills. Enter an unexpected hero from the 1970s: psychedelics. As Anne Buot, a cognitive neuroscience post-doc, puts it, “Psychedelics, a family of psychotropic drugs, are making a comeback.” But there's a catch. Their legal status in many countries makes robust research a challenge.

Now, if you're picturing lab-coated scientists impatiently tapping their feet, you're not far off. The need for solid preliminary data is pressing. Especially when the shadow of potential misuse looms large, with the risk of patients bypassing proven treatments.

‍

A Dive into the Psychedelic Experience

Using psychedelics isn't just popping a pill; it's a journey. A few hours where reality is not just bent but twisted, turned, and sometimes even torn apart. This profound alteration can be a double-edged sword, offering both a break from past traumas and the birth of new thought processes.

While traditional treatments like antidepressants are akin to a slow-burning candle, the effects of psychedelics are more like fireworks, immediate and intense. But as Buot points out, “The connection between this intense experience and actual therapeutic outcomes? Still a mystery.”

Buot and her colleagues reported their findings recently in Scientific Reports through an article entitled “Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.”

“We designed a retrospective online survey to explore, in the general population using psychoactive drugs, their impact on OCD symptoms. We also assessed the attitude of the participants towards the substance in terms of frequency of intakes,” the authors wrote. “In a sample of 174 participants, classic psychedelics were reported as the only substances effective at reducing OCD symptoms. In classic psychedelics users, symptom reduction was associated with the intensity of acute effects, itself correlated to the dose. Reports on the persistence of the therapeutic effect varied from weeks to months, but we could not find any predicting factor.”

The authors went on to state that “Finally, the occurrence and frequency of subsequent intakes, which seemed to be limited in our sample, were predicted by the magnitude and persistence of the therapeutic effect, respectively.”

LSD and psilocybin, the latter a gift from hallucinogenic mushrooms, are the frontrunners in this race against OCD. As psychiatrist Luc Mallet notes, they play with our serotonin receptors. But the data? Still in its infancy.

To bridge this gap, researchers turned to those who've danced with these substances. Their goal? Gauge any perceived symptom relief post-LSD or psilocybin use. After all, in the absence of hard data, patient experiences are the next best thing.

‍

The Promise and Pitfalls of Psychedelics

Buot and her team dove deep, surveying 174 individuals with OCD symptoms who had experimented with psychedelics. The findings? A notable reduction in obsessive thoughts, rituals, and anxiety. Mallet chimes in, “A promising 30% even felt these effects for over three months.” But here's where it gets interesting: the intensity of the trip and its enjoyment seemed tied to the dosage.

But let's pump the brakes. This is subjective data, and it comes with its own set of challenges. The very nature of a psychedelic trip, with its euphoria and altered perceptions, can skew perceptions. Mallet warns, “Many of these individuals are at a therapeutic crossroads, hoping for a miracle. This can color their experiences.”

‍

The Road Ahead: From Anecdotes to Action

The psychedelic experience is a tapestry of personal history, cultural nuances, and vivid imagination. Disentangling its therapeutic potential from this rich backdrop is crucial. Buot believes a multidisciplinary approach, blending ethnography with psychology, might be the key.

The endgame? Harnessing the potential of psychedelics while understanding their long-term biological impact. There's a hint they might boost neuroplasticity, reshaping synaptic connections. But in this thrilling field, every discovery is a step into the unknown.

‍